Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Other Non-Current Liabilities (2020 - 2023)

Terns Pharmaceuticals' Other Non-Current Liabilities history spans 4 years, with the latest figure at $1.1 million for Q3 2023.

  • For Q3 2023, Other Non-Current Liabilities rose 56.84% year-over-year to $1.1 million; the TTM value through Sep 2023 reached $1.1 million, up 56.84%, while the annual FY2022 figure was $1.1 million, 36.09% up from the prior year.
  • Other Non-Current Liabilities reached $1.1 million in Q3 2023 per TERN's latest filing, up from $1.1 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $1.1 million in Q3 2023 to a low of $654000.0 in Q1 2021.
  • Average Other Non-Current Liabilities over 4 years is $837416.7, with a median of $768000.0 recorded in 2021.
  • Peak YoY movement for Other Non-Current Liabilities: grew 6.62% in 2022, then skyrocketed 56.84% in 2023.
  • A 4-year view of Other Non-Current Liabilities shows it stood at $657000.0 in 2020, then grew by 19.79% to $787000.0 in 2021, then skyrocketed by 36.09% to $1.1 million in 2022, then increased by 3.83% to $1.1 million in 2023.
  • Per Business Quant, the three most recent readings for TERN's Other Non-Current Liabilities are $1.1 million (Q3 2023), $1.1 million (Q2 2023), and $1.1 million (Q1 2023).